Characterization and Reliability of $^{[18}F]2$FNQ1P in Cynomolgus Monkeys as a PET Radiotracer for Serotonin 5-HT$_6$ Receptors

Véronique Sgambato-Faure$^{1,2}$, Thierry Billard$^{1,3}$, Elise Météreau$^{1,2}$, Sandra Duperrier$^{1,2}$, Sylvain Fieux$^{1,4}$, Nicolas Costes$^{5}$, Léon Tremblay$^{1,2}$ and Luc Zimmer$^{1,4,5,6,*}$

$^1$Université Claude Bernard Lyon I, Lyon, France, $^2$Institut des Sciences Cognitives Marc Jeannerod, CNRS UMR5229, Bron, France, $^3$Institut de Chimie et de Biochimie, CNRS UMR5246, Villeurbanne, France, $^4$Centre de Recherche en Neurosciences de Lyon, CNRS UMR5292, Inserm U1028, Lyon, France, $^5$CERMEN-Imagerie du Vivant, Lyon, France, $^6$Hospices Civils de Lyon, Lyon, France

Brain serotonin-6 receptor (5-HT$_6$R) is the one of the most recently identified serotonin receptors. Accumulating evidence suggests that it is a potent therapeutic target for psychiatric and neurological diseases. Since $^{[18}F]2$FNQ1P was recently proposed as the first fluorinated positron emission tomography (PET) radioligand for this receptor, the objective of the present study was to demonstrate its suitability for 5-HT$_6$R neuroimaging in primates. $^{[18}F]2$FNQ1P was characterized by in vitro autoradiography and in vivo PET imaging in cynomolgus monkeys. Following in vivo PET imaging, tracer binding indices were computed using the simplified reference tissue model and Logan graphical model, with cerebellum as reference region. The tracer binding reproducibility was assessed by test–retest in five animals. Finally, specificity was assessed by pre-injection of a 5-HT$_6$R antagonist, SB258585. In vitro, results showed wide cerebral distribution of the tracer with specificity toward 5-HT$_6$Rs as binding was effectively displaced by SB258585. In vivo brain penetration was good with reproducible distribution at cortical and subcortical levels. The automated method gave the best spatial normalization. The Logan graphical model showed the best tracer binding indices, giving the highest magnitude, lowest standard deviation and best reproducibility and robustness. Finally, 5-HT$_6$R antagonist pre-injection significantly decreased $^{[18}F]2$FNQ1P binding mainly in the striatum and sensorimotor cortex. Taken together, these preclinical results show that $^{[18}F]2$FNQ1P is a good candidate to address 5-HT6 receptors in clinical studies.

Keywords: PET imaging, serotonin, 5-HT$_6$ receptor, striatum, non-human primate

INTRODUCTION

Serotonin (5-hydroxytryptamine, 5-HT) is a central neurotransmitter involved in a wide variety of physiological functions, as well as in neurological and psychiatric disorders. Pharmacological studies identified numerous serotonergic receptor families and subtypes, classified by structural, functional and pharmacological criteria into seven distinct receptor classes (5-HT$_1$–7) (Beaudoin-Gobert and Sgambato-Faure, 2014). Of these, the 5-HT$_6$ receptor (5-HT$_6$R) is a G protein-coupled receptor that has recently emerged as a new target for neuropsychopharmacology. The exclusive
brain localization of this receptor (Woolley et al., 2004), its role at the interface of signaling pathways (Dawson, 2011; Dayer et al., 2015) and, finally, its presence in the pharmacological spectra of several psychotropic drugs have led to the suggestion that it may have applications in the treatment of various psychiatric disorders (Arnt and Olsen, 2011). More recently, it appeared that 5-HT₆Rs is involved in memory (Meneses, 2014), cognitive processes (Benhamù et al., 2014) and regulation of food intake (Heal et al., 2011), reinforcing its status as an emerging target for anti-dementia and anti-obesity therapeutic agents. According to the United States and European trial databases, more than 20 clinical studies of 5-HT₆Rs are currently open or have been recently completed, evidencing that 5-HT₆Rs antagonists have a symptomatic efficacy profile that can be differentiated from that of currently used agents (cholinesterase inhibitors and the NMDA-antagonist, memantine) (Benhamù et al., 2014; Claeyse et al., 2013). Despite the fact that 5-HT₆Rs functionality is much more complex than initially thought, it is now quite evident that this receptor has great pharmaceutical potential in terms of cognition enhancement.

Positron emission tomography (PET) is a powerful functional imaging modality using a radioligand (ligand coupled to radioactive isotope) that enables visualization and assessment of the distribution/density of a targeted receptor in a living subject (animal or human) (Lancet and Zimmer, 2010; Zimmer and Luxen, 2012). PET is an important tool for elucidating the mechanisms underlying brain disease and enhancing basic and clinical research in neuropharmacology, particularly in Alzheimer’s disease (Bao et al., 2017). There is therefore a critical need for a specific PET radiopharmaceutical for molecular imaging of 5-HT₆Rs.

5-HT₆Rs was first visualized in rats, pigs and humans by in vitro autoradiography using 5-HT₆R antagonists [³H]Ro 63-0563 and [¹²⁵I]SB258585 (Boess et al., 1998; Sleight et al., 1998; Hirst et al., 2000; East et al., 2002; Hirst et al., 2003; Marazziti et al., 2013), with a finding of relative abundance of 5-HT₆R-like immunoreactivity in extrapyramidal and limbic areas in rodents (Gérard et al., 1997; Roberts et al., 2002). More recently, regional distribution and associated neuronal or glial expression were investigated on human post-mortem tissue by both autoradiography with [¹²⁵I]SB258585 and immunohistochemistry (Marazziti et al., 2012, 2013). Taken together, these cross-species studies, although excluding non-human primates, revealed high levels in the striatum, moderate levels in the hippocampus and cerebral cortex and low levels in the cerebellum. In PET imaging studies, only two 5-HT₆R ligands have been successfully used in vivo: [¹¹C]GSK215083, which binds to striatal 5-HT₆Rs in pigs, baboons and humans but displays high affinity for 5-HT₂A Rs essentially in the frontal cortex (Parker et al., 2012, 2015) and [¹⁸F]2FNQ1P, recently developed by our team, that binds with high affinity and specificity to 5-HT₆Rs in cats and macaques and, interestingly, no affinity for 5-HT₂A Rs, nor 5-HT₁B Rs, 5-HT₂B Rs and 5-HT₃C Rs (Becker et al., 2014; Colomb et al., 2014).

Given the paucity of available information on the expression of 5-HT₆Rs in cynomolgus monkeys and the potential transposition of the PET tracer [¹⁸F]2FNQ1P to humans for clinical investigation, the present study sought to characterize the precise distribution of [¹⁸F]2FNQ1P in cynomolgus monkeys at both cortical and subcortical levels. In vitro autoradiography demonstrated the cerebral distribution of the tracer and its specificity toward 5-HT₆Rs. Following in vivo PET imaging, indices of tracer binding were computed using different models and methods of spatial normalization to identify the best method of analysis. To assess the reproducibility and specificity of the tracer, a test–retest reliability study was performed. Finally, the effects of pre-injection with the 5-HT₆R antagonist SB258585 were investigated. All these experiments have the aim to demonstrate that the radiopharmaceutical profile of [¹⁸F]2FNQ1P is suited to studies in human subjects, as 5-HT₆R exhibits a high degree of interspecies homology between macaques and humans (present data and Hirst et al., 2000; Marazziti et al., 2012, 2013; Becker et al., 2014).

MATERIALS AND METHODS

Animals

Five healthy male cynomolgus monkeys (Macaca fascicularis) between 4 and 5 years old (young adults) and weighing between 3.4 and 7.4 kg were used. They were kept under standard conditions (12-h light cycles, 23° C and 50% humidity). Food and water were available ad libitum. All studies were carried out in accordance with European Communities Council Directive (2010/63/EU) as well as the recommendations of the French National Committee (2013/113) and the local animal ethics committee (CELYNE, C2EA-43). For the in vitro part of the study, following the “3Rs” rule (Reduction, Refinement, and Replacement) for animal experimentation, post-mortem tissue from previous studies was used (Beaudoin-Gobert et al., 2015; Sgambato-Faure et al., 2016).

Drugs

SB258585 hydrochloride was obtained from Sigma–Aldrich (Saint Quentin Fallavier, France). For in vivo experiments, SB258585 was injected through a saphenous vein catheter at a concentration of 1.5 mg/kg, 10 min before the intravenous injection of the tracer (Becker et al., 2014).

[¹⁸F]2FNQ1P Radiolabeling and Quality Controls

2FNQ1P precursor was synthesized in the institute of chemistry and biochemistry (Lyon, France) and the radiolabeling was made in the radiopharmacy unit of the CERMEP-imaging platform according to our recently published protocol (Becker et al., 2014; Colomb et al., 2014). Quality control consisted in determining radiochemical purity and specific activity by analytical HPLC assay of an aliquot of the radiolabeled product, with comparison to the calibration curve generated from solutions of known concentrations.

In Vitro Autoradiography

In vitro autoradiography was performed on post-mortem tissue from three cynomolgus monkeys. Briefly, serial 50-μm-coronal...
sections from paraformaldehyde-fixed brain were mounted on glass slides, and allowed to air-dry before storage at −20°C until use. On the day of radiotracer synthesis, the slides were allowed to reach room temperature and were then incubated for 20 min in Tris phosphate-buffered saline (138 mM NaCl, 2.7 mM KCl, pH adjusted to 7.6) containing 37 kBq/mL (1 mCi/mL) \(^{[18}F\)]2FNQ1P. For competition experiments, the slides were placed in the same buffer supplemented with SB258585 (the selective 5-HT\(_6\)R antagonist) at a concentration of 10 nM. After incubation, slides were dipped in cold buffer (4°C), then in cold distilled water (4°C), and dried and placed on a phosphor imaging plate for 60 min (BAS-5000; Fujifilm).

**In Vivo Image Acquisition**

Positron emission tomography and MRI acquisitions were performed in anesthetized *cynomolgus* monkeys [atropine at 0.05 mg/kg i.m., followed 15-min later by zoletil at 15 mg/kg i.m. as previously (Beaudoin-Gobert et al., 2015)].

Anatomical MRI acquisition comprised a 13-min 3D anatomic T1-weighted sequence using a 1.5-T Magnetom scanner (Siemens, MRI department of the CERMEP imaging platform). The MPRAGE sequence was used with the following acquisition parameters: TE = 2.89 ms, TR = 2160 ms, IT = 1100 ms, flip angle = 15°, FoV = 154 mm, matrix size = 256 × 256, number of acquisitions = 2. The anatomical volume covered the whole brain, with 176 planes of 0.6 mm cubic voxels.

Positron emission tomography imaging was performed using a Siemens Biograph mCT/S64 scanner (PET department of the CERMEP imaging platform) with spatial transverse resolution of 4.4 mm (Jakoby et al., 2011). Attenuation was obtained using a 1-min low-dose CT-scan, acquired before emission. Dynamic acquisition started with the i.v. injection of the radiotracer (mean dose ± SEM: 123 ± 11.9 MBq) and lasted 90 min. Biograph mCT/S64 emission images were reconstructed using the Siemens ultraHD PET algorithm with 12 iterations, 8 subsets and a zoom factor of 21. Reconstructed volumes were 109 slices (2.027 mm thickness, 256 × 256 × 256 voxels), in a series of 28 sequential-frame series of increasing duration from 30 s to 5 min. Each monkey underwent two \(^{[18}F\)]2FNQ1P injections (test and retest) separated by a period ranging from 2 to 13 weeks. In addition, three monkeys underwent an additional \(^{[18}F\)]2FNQ1P acquisition [before (around 1 month) or after (between 1 and 3 months) the retest] to study the effects of a pre-injection of SB258585, a 5-HT\(_6\)R antagonist.

**Image Processing**

**Regions of Interest Delineation**

Region delineation used the *M. fascicularis* atlas implemented with the MAXPROB method (Ballanger et al., 2013). For data clarity, some regions were grouped together as follows: anterior cingulate cortex (ACC24/32 + ACC25); prefrontal cortex (dPFC + vPFC + mPFC); sensorimotor cortex (S1 + M1 + premotor cortex); parahippocampal and entorhinal cortices; temporal (superior + middle + inferior cortices); parietal cortex (superior + inferior parietal); anterior striatum (anterior caudate + anterior putamen + ventral striatum) and posterior striatum (posterior caudate + posterior putamen + ventral posterior putamen). For each individual animal, PET scans were summed over frames, before being registered between PET acquisitions to provide an averaged PET image. Two different methods of spatial normalization were used and compared: (i) a manual method in which the PET image is manually co-registered on the *M. fascicularis* MRI template (affine transformation performed with four points located at various brain positions); (ii) an automatic method, in which the averaged PET image is automatically co-registered on the individual MRI (rigid transformation), and the individual MRI automatically co-registered on the MRI template (affine + non-linear transformations). Direct and inverse transformations were concatenated to directly resample template and atlases in the individual native spaces, or reciprocally normalize PET data to the template space.

**Kinetic Modeling**

Positron emission tomography studies were analyzed by suitable tracer kinetics modeling at regional and voxel-based level. The parameters computed were: non-displaceable binding potential (BP\(_{ND}\)), using the simplified reference tissue model (SRTM) (Gunn et al., 1997) and the distribution volume ratio (DVR), using the Logan Reference model (Logan, 2000) calculated using frames from 0 to 90 min. As defined by Innis et al. (2007), in vivo BP\(_{ND}\) refers to the concentration ratio at equilibrium of specifically bound radioligand to that of non-displaceable radioligand in tissue. BP\(_{ND}\) is the typical measurement from reference tissue methods, as it compares the concentration of radioligand in receptor-rich to receptor-free regions. Compartmental modeling also established that BP\(_{ND}\) is equal to the \(f_{NS,k_{on}B_{avail}}/k_{off}\). So BP\(_{ND}\) is linked to the available receptor density and the affinity of the radioligand for its specific receptor. As previous data from Parker and collaborators (Parker et al., 2012, 2015) support the use of the cerebellum as a region of reference for high affinity 5-HT\(_6\)R ligands, the cerebellum (excluding vermis) was used as the reference area for both models. Regional parametric values were obtained by modeling the mean regional kinetics, extracted in the native PET spaces with the MAXPROB method. Whole-brain parametric images were obtained by modeling kinetics at the voxel level. Parametric images were transformed to the common template space.

**Reproducibility**

The reliability of the BP indices derived from the SRTM and Logan Model (BP = DVR−1) was assessed by computation of three reproducibility indices from the test–retest measurements: (i) percentage change in mean (relative bias): percentage change calculated as the difference between test and retest values divided by the test value; this index includes random changes and systematic biologic error; (ii) typical error or within-subject SD of the bias, expressed as percentage of the mean: the typical error is calculated as the standard deviation of the differences between BP\(_{ND}\) test and BP\(_{ND}\) re-test, divided by the square root of the number of measurements; (iii) intra-class correlation coefficient (ICC) estimating respect of rank in a test–retest study: this depends on the size and the quality of the sample in the
population: ICC = (MSBS − MSWS)/(MSBS + MSWS), where MSBS is the mean sum of squares between subjects, and MSWS is the mean sum of squares within subjects.

Statistical Analyses
All statistical analyses were performed using STATA software version 10.1. For autoradiography, for which data were represented as mean ± SEM, a paired t-test was used to attest the effect of the antagonist on selected regions of interest. For PET imaging, the whole-brain analysis was adjusted using the Bonferroni correction according to the number of regions of interest included.

RESULTS

$[{^{18}}\text{F}]2\text{FNQ1P}$ Radiosynthesis
Automated radiolabeling of 2FNQ1P leading to $[{^{18}}\text{F}]2\text{FNQ1P}$ was performed from its nitro-precursors at 150°C, with a radiochemical yield of 36% corrected for decay and 80–100 min radiosynthesis time (including HPLC purification and formulation). No radioactive by-products were observed and the HPLC conditions ensured good separation of the radiotracer from its respective nitro-precursor, as confirmed on quality control. Radiochemical purity was better than 98% and specific activity of $[{^{18}}\text{F}]2\text{FNQ1P}$ was between 100 and 150 GBq/µmol, corrected at EOS.

$[{^{18}}\text{F}]2\text{FNQ1P}$ In Vitro Autoradiography
The in vitro autoradiography data evidenced a wide distribution of $[{^{18}}\text{F}]2\text{FNQ1P}$ in post-mortem tissue (Figure 1). The tracer bound to both cortical and subcortical areas, along the rostro-caudal axis of the brain. High binding levels were especially detected in the frontal cortex, anterior cingulate cortex, orbitofrontal cortex, basal ganglia, hippocampus and thalamus. Within the basal ganglia, high-to-moderate binding was detected in the striatum and pallidum, and in the subthalamic nucleus and substantia nigra. Lower levels of binding were observed in the insula, amygdala, raphe nuclei and periaqueductal region, parietal, occipital and temporal cortices, and the cerebellum. Interestingly, binding was substantially diminished in all regions after competition with SB258585 at a dose of 10 nM (Figure 1) (higher doses did not enhance this displacement; data not shown), demonstrating the sensitivity of $[{^{18}}\text{F}]2\text{FNQ1P}$ toward 5-HT$_6$Rs, and encouraging in vivo investigation.

$[{^{18}}\text{F}]2\text{FNQ1P}$ PET Imaging
As shown in Figure 2, a high $[{^{18}}\text{F}]2\text{FNQ1P}$ BP$_{ND}$ was observed at baseline in primate brain regions, such as the...
prefrontal cortical areas, anterior cingulate cortex, striatum (ventral striatum, caudate nucleus, and putamen), thalamus, premotor and motor cortices. Additionally, moderate-to-low tracer fixation was detected in other cortical (parietal, temporal) and subcortical (amygdala, raphe nuclei) regions. Finally, binding is observed at the level of the eyes and salivary glands but not in the skull (Figure 2).

Models and Methods of Spatial Normalization
Two models (SRTM and Logan) and two methods of spatial normalization (manual and automated) were compared, using three reproducibility indices: percentage change in mean, typical error and intra-class correlation coefficient (ICC). Combining all regions, change in mean progressively decreased from 35% (manual method and Logan model) to 6% (automated method and Logan model) (data not shown). Typical error diminished from 11% with the manual method to 5% with the automated method, independently of model (SRTM or Logan) (data not shown). Finally, ICC increased from 0.52 (manual method and SRTM model) to 0.58 (manual method and Logan model), reaching 0.69 with the automated method and SRTM model and 0.68 with the automated model and Logan model (data not shown).

Test–Retest Reliability
Using manual spatial normalization and the SRTM model (data not shown), the \(B_{\text{NDD}}\) in test and retest ROIs went from \(0.20 \pm 0.14\) in the PCC to \(0.78 \pm 0.05\) in the anterior putamen. No difference was found between test and retest in the paired \(t\)-test comparisons. Mean percentage change by region went from \(-30\%\) in the ACC to \(148\%\) in the PFC, with a range of typical error from \(3\%\) in the temporal cortex to \(26\%\) in the parietal cortex. ICC went from \(-0.17\) in the amygdala to \(0.83\) in the temporal cortex. Using manual normalization and the Logan model (data not shown), \(B_{\text{NDD}}\) in test and retest ROIs went from \(0.16 \pm 0.10\) in the internal pallidum to \(0.76 \pm 0.07\) in the anterior putamen, with no significant difference. Mean percentage change by region

**FIGURE 2** | \([^{18}F]2FNQ1P BP_{\text{ND}}\) in vivo distribution in macaque brain. Spatially normalized parametric images of \([^{18}F]2FNQ1P BP_{\text{ND}}\) were averaged over five monkeys. The resulting mean image was superimposed on the *Macaca fascicularis* brain MRI template. Twelve coronal slices along the antero-caudal axis are shown. Colors represent the level of non-displaceable binding potential using the cerebellum as reference region, with the medial and ventrolateral prefrontal cortex, orbitofrontal cortex, premotor and motor cortices, ventral striatum, caudate nucleus, putamen, hippocampus and thalamus showing the highest binding values. Outside the brain, \([^{18}F]2FNQ1P\) binding is observed in the eyes and salivary glands but not in the skull.

---

Sgambato-Faure et al. ([18]F)2FNQ1P as a 5-HT6 Radiotracer in Non-human Primates
went from −7% in the parahippocampal and entorhinal cortices to 150% in the internal pallidum, with a range of typical error from 7% in the ventral striatum and temporal cortex, to 18% in the PFC. ICC went from 0.16 in the amygdala to 0.86 in the ventral striatum. Using automated normalization with the SRTM model (data not shown), BP\textsubscript{ND} in test and retest ROIs went from 0.13 ± 0.07 in the raphe to 0.67 ± 0.05 in the anterior putamen, with no significant difference. Mean percentage change by region went from −20% in the parahippocampal and entorhinal cortices to 43% in the raphe, with a range of typical error from 2% in the insula to 11% in the raphe. ICC went from 0.08 in the raphe to 0.97 in the PFC. Finally, using automated method and Logan model (Table 1 and Figure 3), the BP\textsubscript{ND} in test and retest ROIs went from 0.14 ± 0.02 in the raphe to 0.70 ± 0.05 in the anterior putamen, again with no significant difference. Mean percentage change by region went from −20% in the parahippocampal and entorhinal cortices to 27% in the raphe with a range of typical error from 2% in the temporal to 10% in the raphe. ICC ranged from 0.16 in the raphe to 0.97 in the prefrontal cortex. Of note, [\textsuperscript{18}F]2FNQ1P exhibited BP\textsubscript{ND} less than 1 as other serotonergic tracers ([\textsuperscript{18}F]MPPF and [\textsuperscript{11}C]GSK215083), which are used for \textit{in vivo} imaging in both animals and humans studies (Yamamoto et al., 2013; Parker et al., 2015; Ballanger et al., 2016).

### Pre-injection of 5-HT\textsubscript{6}R Antagonist SB258585

The specificity of [\textsuperscript{18}F]2FNQ1P was tested by investigating the impact of pre-injection of SB258585 at a dose of 1.5 mg/kg, higher doses inducing cardiovascular manifestations such as breathing apnea in cat (Zimmer, personal communications). [\textsuperscript{18}F]2FNQ1P BP\textsubscript{ND} levels were significantly reduced in the striatum and sensorimotor cortex using a \textit{p}-value threshold of 0.003 (i.e., 0.05/14 regions) to account for multiple comparison (Table 2). Decreases of [\textsuperscript{18}F]2FNQ1P BP\textsubscript{ND} were also observed in the ACC, PFC, Insula and parietal cortex with uncorrected \textit{p}-value threshold (Table 2). These qualitative reductions of binding are illustrated in Figure 4. There were no correlation between [\textsuperscript{18}F]2FNQ1P binding at baseline and the percentage of change in mean (\textit{p} = 0.25, data not shown), evidencing that regions with high binding are not systematically the ones for which SB258585 displaced the more efficiently the radioligand.

### Table 1 | Test–retest characteristics of BP\textsubscript{ND} computed with automatic spatial registration and the Logan model.

| Table 1 | Test–retest characteristics of BP\textsubscript{ND} computed with automatic spatial registration and the Logan model. |
|----------|-------------------------------------------------------------------------------------------------|
| BP Region | Test (mean ± SEM) | Retest (mean ± SEM) | Change in mean (%) | Typical error (%) | ICC | Wilcoxon rank-sum test adjusted \textit{P} |
| ACC      | 0.50 ± 0.05       | 0.48 ± 0.07       | 8.67               | 5.09              | 0.88 | 1.000 |
| PCC      | 0.35 ± 0.05       | 0.33 ± 0.06       | 6.81               | 3.74              | 0.90 | 1.000 |
| OFC      | 0.31 ± 0.05       | 0.30 ± 0.05       | 6.19               | 3.44              | 0.91 | 1.000 |
| PFC      | 0.34 ± 0.08       | 0.31 ± 0.07       | 12.99              | 2.66              | 0.97 | 1.000 |
| Insula   | 0.53 ± 0.05       | 0.48 ± 0.04       | 9.32               | 2.54              | 0.93 | 1.000 |
| Sensorimotor | 0.41 ± 0.10       | 0.31 ± 0.06       | 24.63              | 6.80              | 0.86 | 0.995 |
| Temporal | 0.25 ± 0.03       | 0.26 ± 0.02       | −3.23              | 2.44              | 0.78 | 1.000 |
| Parietal | 0.35 ± 0.09       | 0.31 ± 0.07       | 11.35              | 6.33              | 0.88 | 1.000 |
| Mean Neocortex | 0.38 ± 0.06       | 0.35 ± 0.06       | 9.59               | 4.13              | 0.89 | 0.99 |
| Caudate, anterior | 0.59 ± 0.03       | 0.55 ± 0.05       | 7.86               | 4.78              | 0.77 | 1.000 |
| Caudate, posterior | 0.45 ± 0.03       | 0.43 ± 0.05       | 4.21               | 4.97              | 0.65 | 1.000 |
| Putamen, anterior | 0.70 ± 0.05       | 0.66 ± 0.05       | 5.68               | 4.05              | 0.88 | 1.000 |
| Putamen, posterior | 0.55 ± 0.03       | 0.53 ± 0.03       | 4.90               | 5.30              | 0.46 | 1.000 |
| Putamen, posterior ventral | 0.46 ± 0.03       | 0.44 ± 0.03       | 4.79               | 4.89              | 0.46 | 1.000 |
| Ventral Striatum | 0.57 ± 0.03       | 0.54 ± 0.03       | 4.53               | 4.77              | 0.45 | 1.000 |
| Pallidum, external | 0.31 ± 0.02       | 0.3 ± 0.04        | 0.72               | 6.01              | 0.26 | 1.000 |
| Pallidum, internal | 0.18 ± 0.03       | 0.18 ± 0.04       | 7.33               | 5.10              | 0.47 | 1.000 |
| Mean Basal Ganglia | 0.48 ± 0.03       | 0.46 ± 0.04       | 5.00               | 4.98              | 0.55 | 1.00 |
| Thalamus | 0.47 ± 0.05       | 0.41 ± 0.05       | 14.26              | 3.81              | 0.87 | 0.905 |
| Amygdala | 0.32 ± 0.04       | 0.34 ± 0.05       | −3.97              | 2.90              | 0.90 | 1.000 |
| Hippocampus | 0.46 ± 0.03       | 0.45 ± 0.05       | 2.38               | 4.38              | 0.79 | 1.000 |
| Parahip/Entorhinal | 0.23 ± 0.04       | 0.26 ± 0.03       | −17.16             | 5.57              | 0.54 | 1.000 |
| Raphe    | 0.14 ± 0.02       | 0.15 ± 0.06       | 26.83              | 9.60              | 0.16 | 1.000 |
| Mean Other areas | 0.32 ± 0.03       | 0.32 ± 0.05       | 4.47               | 5.25              | 0.65 | 0.98 |
| All regions | 0.40 ± 0.04       | 0.38 ± 0.05       | 6.62               | 4.72              | 0.70 | 0.99 |
| Cerebellum | −0.01 ± 0.00      | −0.01 ± 0.00      | −12.92             | 0.29              | 0.90 | 1.000 |

ACC includes ACC24/32 and ACC25. PFC includes dPFC, vPFC and mPFC. Sensorimotor includes S1, M1, and PMC. Parietal includes superior parietal, inferior parietal and precuneus. Anterior striatum includes anterior caudate, anterior putamen, and ventral striatum; posterior striatum includes posterior caudate, posterior putamen and ventral posterior putamen. Bold values correspond to the mean of the above cited sub-regions.
DISCUSSION

The serotonin system has been implicated in a variety of psychiatric and neurological disorders, and drugs targeting the 5-HT neurotransmitter system are commonly used to treat depression and anxiety. Serotonin 5-HT6R is one of the most recently discovered serotonin receptors almost exclusively localized in the brain (Woolley et al., 2004). 5-HT6Rs are increasingly reported to be involved in pathophysiological processes and possible therapeutics. Several pharmaceutical and biotech companies are currently developing new drugs specifically targeting this receptor: antipsychotics in schizophrenia, procognitive drugs in Alzheimer’s or Parkinson’s disease and dementia, and appetite suppressant drugs in obesity (Bali and Singh, 2015). There is therefore a critical need for a specific PET radiopharmaceutical suitable to the molecular imaging of this receptor. Ideally, a PET tracer is labeled with fluorine 18, which allow transfer to PET nuclear pharmacies and PET imaging centers, allowed thanks to its half-life ($T_{1/2} = 110$ min). Our recent data showed revealed that the 5-HT6R PET radiotracer our team developed, $[^{18}F]2FNQ1P$, was the first to show satisfactory 5-HT6R selectivity and brain distributions consistent with known 5-HT6R density patterns in a feline model (Becker et al., 2014). Because 5-HT6R exhibits a high degree of interspecies homology between non-human primates and humans, and in order to reinforce the argument for transfer to clinical studies (first-in-man study), we characterized this radiotracer in cynomolgus monkeys, a non-human primate model classically used in translational studies in neuroscience. This test–retest reliability study of $[^{18}F]2FNQ1P$ binding was therefore designed to support interpretation of future preclinical and clinical studies, emphasizing the radiotracer binding pattern, reproducibility and precision of binding. The aim was to generate reliable and reproducible parameters to allow application in both cross-sectional and longitudinal studies.

Interestingly and encouragingly for translational purposes, the PET images were in agreement with the in vitro autoradiography data, confirming that $[^{18}F]2FNQ1P$ binds in a pattern exquisitely in accordance with cortical and subcortical 5-HT6R locations. Our in vitro results are in agreement with previous rodent and human studies showing higher 5-HT6 binding (and 5-HT6R mRNA) in the whole striatum compared to frontal and subcortical regions, and lower binding (and 5-HT6R mRNA) in the cerebellum (Roberts et al., 2002; Hirst et al., 2003; Marazziti et al., 2013). Further, the 5-HT6 selectivity of $[^{18}F]2FNQ1P$’s in vivo binding was confirmed in the blocking study, in which striatal and cortical binding was decreased by a bolus of SB258585, a specific 5-HT6R antagonist, particularly in receptor-rich regions. Last and not least, this radioligand highly binds to cortical and subcortical regions, which are involved in behavioral disorders (Sgambato-Faure et al., 2016), strengthening the interest to study the potential therapeutic role of 5-HT6Rs in such disorders. Regions of potential interest for the use of this radiotracer are the striatum, thalamus and hippocampus, and the frontal, orbitofrontal, anterior cingulate, sensorimotor and insular cortices. The frontal cortex and hippocampus are regions critically involved in cognitive processing. However, the highest levels of 5-HT6Rs were found in motor and limbic regions of...
TABLE 2 | Effect of SB258585 pre-injection on BP_{ND} characteristics using manual and automatic spatial registrations with the Logan model.

| Region             | Baseline (mean ± SEM) | Antago (mean ± SEM) | Change in mean (%) | SD change in mean (%) | Wilcoxon rank-sum test P-value |
|--------------------|-----------------------|---------------------|--------------------|---------------------|-------------------------------|
| Anterior striatum  | 0.65 ± 0.10           | 0.45 ± 0.07         | −28.85             | 13.13               | 0.0002***                    |
| Posterior striatum | 0.54 ± 0.12           | 0.42 ± 0.07         | −57.85             | 13.61               | 0.0002***                    |
| Pallidum           | 0.28 ± 0.08           | 0.20 ± 0.08         | −28.55             | 9.93                | 0.0076*                      |
| ACC                | 0.49 ± 0.11           | 0.27 ± 0.06         | −40.33             | 21.76               | 0.1159                       |
| OFC                | 0.34 ± 0.11           | 0.27 ± 0.06         | −22.89             | 17.69               | 0.0069*                      |
| PFC                | 0.43 ± 0.18           | 0.38 ± 0.16         | −12.10             | 19.45               | 0.046*                       |
| Insula             | 0.57 ± 0.11           | 0.43 ± 0.07         | −26.02             | 16.80               | 0.0002***                    |
| Sensorimotor       | 0.52 ± 0.20           | 0.30 ± 0.07         | −40.32             | 42.73               | 0.3134                       |
| Temporal           | 0.32 ± 0.16           | 0.33 ± 0.13         | −3.58              | 25.76               | 0.0414*                      |
| Parietal           | 0.48 ± 0.25           | 0.33 ± 0.08         | −26.02             | 16.04               | 0.2489                       |
| Thalamus           | 0.51 ± 0.10           | 0.42 ± 0.03         | −9.04              | 42.87               | 0.9165                       |
| Amygdala           | 0.33 ± 0.10           | 0.34 ± 0.05         | −3.58              | 25.87               | 0.3554                       |
| Hippocampus        | 0.44 ± 0.10           | 0.42 ± 0.06         | −3.73              | 9.88                | 1.0000                       |
| Cerebellum         | −0.01 ± 0.05          | −0.01 ± 0.07        | −3.67              | 62.04               |                               |

Baseline refers here to the mean of test and re-test BP_{ND}. ACC includes ACC24/32 and ACC25. PFC includes dPFC, vPFC, and mPFC. Sensorimotor includes S1, M1, and PMC. Anterior striatum includes anterior caudate, anterior putamen and ventral striatum; posterior striatum includes posterior caudate, posterior putamen and ventral posterior putamen. Pallidum includes external and internal segments. ** Indicates significant differences after Bonferroni correction for multiple comparison (i.e., p-value < 0.003, n = 14). * Indicates significant difference (i.e., p-value < 0.05, uncorrected).

Because spatial normalization is a critical step in the quantitative analysis of brain radiotracer binding (Matsuda, 2007), several models and methods were compared. In few words, several models are used to explore and quantify radiotracer kinetic in PET (Gunn et al., 1997; Logan, 2000; Innis et al., 2007). These models are formulated by differential equations ruling exchange between plasma and tissue compartments with the frontal cortex and striatum, which could indicate important roles of 5-HT_{6}R in motor functions, motivation and reward processing (Tremblay et al., 2015; Sgambato-Faure et al., 2016).
aim to simplify biological systems. Once a model is formulated, a tracer kinetic assay can provide very sensitive and accurate measurements of the rates of the process.

Our results clearly indicated that the automated method outperforms manual method. For BP computation, the Logan model showed slightly better results than the SRTM approach. We also investigated reproducibility indices separating splitting cerebral regions into neocortex, basal ganglia and other regions. Globally, reproducibility parameters were in favor of the automated normalization methods (higher ICC, lower typical error and bias) in cortical regions.

Compared to similar reproducibility studies published for other PET tracers of the serotonergic system in primates (Chen et al., 2012; Tavares et al., 2014), the reproducibility parameters of $^{18}\text{F}$F2FNQ1P binding potential showed more satisfactory results. In consequence, the ability to detect changes in 5-HT$_6$R availability or occupancy in $\text{in vivo}$ studies, would be more sensitive with $^{18}\text{F}$F2FNQ1P, giving a supplemental chance of elucidating functional and dysfunctional serotonin transmission in the brain and facilitating the development of therapeutic drugs targeting 5-HT$_6$Rs. Again, this sensitivity for detecting changes is a supplementary argument for transferring this radiotracer to human subjects.

However, several methodological points have to be taken into consideration. Firstly, possible modifications of the 5-HT$_6$ receptor occupancy are limited by the robust methodology of the protocol: the same sex and age of the monkeys; the same scheduled time for each PET scans; the absence of any pharmacological treatment or other behavioral experiment during the test–retest period; the normalized anesthesia and monitoring procedures; the reproducible radiopharmaceutical characteristics of the radiotracer. Secondly, for a complete modeling of the $^{18}\text{F}$F2FNQ1P tracer kinetics, one should have the arterial input function of the compartment model. This arterial input function requires arterial blood samples, plasma centrifugation, and metabolites measurement. However, the metabolism of radiotracers is highly dependent on the P450 hepatic cytochromes and knowledge of the metabolite curve in primate experiments is poorly predictive of subsequent clinical studies (Burkina et al., 2017). Since arterial sampling is invasive and is not directly useful for future studies in human, we preferred therefore to restrict the current study to a test–retest and blocking study, which gave us enough knowledge about the $\text{in vivo}$ characteristics of the tracer, while preserving an ethic reducing the intervention on the animal. This approach has already been followed for other serotonin PET tracers, e.g., $^{18}\text{F}$Mefiway, initially evaluated in the primate without arterial sampling (Saigal et al., 2006; Wooten et al., 2011) and later used in humans (Hillmer et al., 2014).

Taken together, the present results indicate that $^{18}\text{F}$F2FNQ1P is a reliable PET tracer for visualization and quantification of brain 5-HT$_6$Rs in cynomolgus monkeys. Although these binding parameters were measured in non-human primates, we think that the radiopharmacological profile of $^{18}\text{F}$F2FNQ1P will be appropriate for studies in human subjects, as 5-HT$_6$R exhibits a high degree of interspecies homology between non-human primates and humans. These data convinced us that a protocol can now be conducted in humans. This protocol will be similar with, in addition, the exploration of the nature of the radioactive metabolites of $^{18}\text{F}$F2FNQ1P and their lipophilicity, determining possible brain penetration. This first-in-man study will ultimately determine the utility of $^{18}\text{F}$F2FNQ1P as a PET ligand for 5-HT$_6$R assessment in humans affected by several brain pathologies and/or treated with 5-HT$_6$R drug candidates.

**AUTHOR CONTRIBUTIONS**

VS-F performed research, analyzed data and wrote the paper. TB performed research. EM analyzed data. SD performed research. SF performed research. NC analyzed data. LT wrote the paper. LZ designed the study and wrote the paper.

**ACKNOWLEDGMENTS**

The authors wish to thank J.-L. Charieau and F. Hérant for expert animal care. The authors also thank F. Lavenne and B. Vidal for participation in data collection. This work was performed within the framework of the LABEX PRIMES (ANR-11-LABX-0063) of Université de Lyon, within the program “Investissements d’Avenir” (ANR-11-IDEX-0007) operated by the French National Research Agency (ANR).

**REFERENCES**

Arnt, J., and Olsen, C. K. (2011). 5-HT6 receptor ligands and their antipsychotic potential. *Int. Rev. Neurobiol.* 96, 141–161. doi: 10.1016/B978-0-12-385902-0.00006-1

Bali, A., and Singh, S. (2015). Serotonergic 5-HT6 receptor antagonists: heterocyclic chemistry and potential therapeutic significance. *Curr. Top. Med. Chem.* 15, 1643–1662. doi: 10.2174/1568026615666150427110420

Ballanger, B., Beaudoin-Gobert, M., Neumane, S., Épinat, J., Météreau, E., Duperrier, S., et al. (2016). Imaging dopamine and serotonin systems on MPTP monkeys: a longitudinal PET investigation of compensatory mechanisms. *J. Neurosci.* 36, 1577–1589. doi: 10.1523/JNEUROSCI.2010-15.2016

Ballanger, B., Tremblay, L., Sgambato-Faure, V., Beaudoin-Gobert, M., Lavenne, F., Le, Bars D, et al. (2013). A multi-atlas based method for automated anatomical

_Macaca fascicularis_ brain MRI segmentation and PET kinetic extraction. *Neuroimage* 77, 26–43. doi: 10.1016/j.neuroimage.2013.03.029

Bao, W., Jia, H., Finnema, S., Cai, Z., Carson, R. E., and Huang, Y. H. (2017). PET imaging for early detection of Alzheimer’s disease: from pathologic to physiologic biomarkers. *PET Clin.* 12, 329–350. doi: 10.1016/j.pet.2017.03.001

Beaudoin-Gobert, M., Épinat, J., Météreau, E., Duperrier, S., Neumane, S., Ballanger, B., et al. (2015). Behavioural impact of a double dopaminergic and serotonergic lesion in the non-human primate. *Brain* 138, 2632–2647. doi: 10.1093/brain/awv183

Beaudoin-Gobert, M., and Sgambato-Faure, V. (2014). Serotonergic pharmacology in animal models: from behavioral disorders to dyskinesia. *Neuropsychopharmacology* 39, 81, 15–30. doi: 10.1016/j.neuropharm.2014.01.031

Becker, G., Colomb, J., Sgambato-Faure, V., Tremblay, L., Billard, T., and Zimmer, L. (2014). Preclinical evaluation of $^{18}\text{F}$F2FNQ1P as the
first fluorinated serotonin 5-HT6 radioligand for PET imaging. Eur. J. Nucl. Med. Mol. Imaging 42, 495–502. doi: 10.1007/s00259-014-2936-y

Benham, B., Martin-Fontecha, M., Vazquez-Villa, H., Pardo, L., and Lopez-Rodriguez, M. L. (2014). Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer’s disease. J. Med. Chem. 57, 7160–7180. doi: 10.1021/jm500395z

Boess, F. G., Riemer, C., Bös, M., Bentley, J., Bourson, A., and Sleight, A. J. (1998). The 5-hydroxytryptamine 6 receptor-selective radioligand [3H]Ro 63–0563 labels 5-hydroxytryptamine receptor binding sites in rat and porcine striatum. Mol. Pharmacol. 54, 577–583.

Burkina, V., Rasmussen, M. K., Pilipenko, N., and Zamaratskaia, G. (2017). Comparison of xenobiotic-metabolising human, porcine, rodent, and piscine cytochrome P450. Toxicology 375, 10–27. doi: 10.1016/j.tox.2016.11.014

Chen, Y. A., Huang, W. S., Lin, Y. S., Cheng, C. Y., Liu, R. S., Wang, S. J., et al. (2012). Characterization of 4-[18F]-ADAM as an imaging agent for SERT in non-human primate brain using PET: a dynamic study. Nucl. Med. Biol. 39, 279–285. doi: 10.1016/j.nucmedbio.2011.08.002

Claeysen, S., Bockaert, J., and Giannoni, P. (2015). Serotonin: a new hope for Parkinson’s disease? J. Neurol. Sci. 350, 1–10. doi: 10.1016/j.jns.2015.02.002

Dawson, L. A. (2011). The central role of 5-HT6 receptors in modulating brain neurochemistry. Int. Rev. Neurobiol. 96, 1–26. doi: 10.1016/B978-0-12-385902-0.00001-2

Dayer, A. G., Jacobsen, M., Chaumont-Dubel, S., and Marin, P. (2015). 5-HT6 receptor: a new player controlling the development of neural circuits. ACS Chem. Neurosci. 6, 951–960. doi: 10.1021/acsn eurosci.5b00013

East, S. Z., Burnet, P. W., Leslie, R. A., Roberts, J. C., and Harrison, P. J. (2002). 5-HT6 receptor binding sites in schizophrenia and following antipsychotic drug administration: autoradiographic studies with [125I]SB-258585. Synpore 45, 191–199. doi: 10.1002/syn.10097

Gérard, C., Martres, M. P., Lefèvre, K., Miquel, M. C., Vergé, D., Lanfumey, L., et al. (1997). Immuno-localization of serotonin 5-HT6 receptor-like material in rat central nervous system. Brain Res. 746, 207–219. doi: 10.1016/S0006-8993(96)01224-3

Gunn, R. N., Lammertsma, A. A., Hume, S. P., and Cunningham, V. J. (1997). Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. NeuroImage 6, 279–287. doi: 10.1016/nien.1997.03.026

Heal, D. A., Gosden, J., and Smith, S. (2011). The 5-HT6 receptor as a target in Alzheimer’s disease? ACS Chem. Neurosci. 6, 940–943. doi: 10.1021/acscenneuro.5b00135

Colomb, J., Becker, G., Fieux, S., Zimmer, L., and Billard, T. (2014). Syntheses, radiolabeling, and in vitro evaluations of fluorinated PET radioligands of 5-HT6 serotoninergic receptors. J. Med. Chem. 57, 3884–3890. doi: 10.1021/jm500372e

Dawson, L. A. (2011). The central role of 5-HT6 receptors in modulating brain neurochemistry. Int. Rev. Neurobiol. 96, 1–26. doi: 10.1016/B978-0-12-385902-0.00001-2

Dayer, A. G., Jacobsen, M., Chaumont-Dubel, S., and Marin, P. (2015). 5-HT6 receptor: a new player controlling the development of neural circuits. ACS Chem. Neurosci. 6, 951–960. doi: 10.1021/acsn eurosci.5b00013

East, S. Z., Burnet, P. W., Leslie, R. A., Roberts, J. C., and Harrison, P. J. (2002). 5-HT6 receptor binding sites in schizophrenia and following antipsychotic drug administration: autoradiographic studies with [125I]SB-258585. Synpore 45, 191–199. doi: 10.1002/syn.10097

Gérard, C., Martres, M. P., Lefèvre, K., Miquel, M. C., Vergé, D., Lanfumey, L., et al. (1997). Immuno-localization of serotonin 5-HT6 receptor-like material in the rat central nervous system. Brain Res. 746, 207–219. doi: 10.1016/S0006-8993(96)01224-3

Gunn, R. N., Lammertsma, A. A., Hume, S. P., and Cunningham, V. J. (1997). Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. NeuroImage 6, 279–287. doi: 10.1016/nien.1997.03.026

Heal, D. A., Gosden, J., and Smith, S. (2011). The 5-HT6 receptor as a target for developing novel antiobesity drugs. Int. Rev. Neurobiol. 96, 73–109. doi: 10.1016/B978-0-12-385902-0.00004-8

Hillmer, A. T., Wooten, D. W., Bajwa, A. K., Higgins, A. T., Wooten, D. W., et al. (2014). First-in-human evaluation of 18F-mefway, a PET radioligand specific to serotonin 1A receptors. J. Nucl. Med. 55, 1973–1979. doi: 10.2967/jnumed.114.145151

Hirst, W. D., Abrahamsen, B., Blaney, F. E., Calver, A. R., Aloj, L., Price, G. W., et al. (2003). Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. Mol. Pharmacol. 64, 1295–1298. doi: 10.1124/mol.64.6.1295

Hirst, W. D., Minton, J. A., Bromidge, S. M., Moss, S. F., Latter, A. J., Riley, G., et al. (2000). Characterization of [125I]-SB-258585 binding to human recombinant and native 5-HT6 receptors in rat, pig and human brain tissue. Br. J. Pharmacol. 130, 1597–1605. doi: 10.1038/sj.bjp.0703458

Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., et al. (2007). Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 27, 1533–1539. doi: 10.1038/jcbfm.9600493

Jakoby, B. W., Bercier, Y., Conti, M., Casey, M. E., Bendriem, B., and Townsend, D. W. (2011). Physical and clinical performance of the mCT time-of-flight PET/CT scanner. Phys. Med. Biol. 56, 2375–2389. doi: 10.1088/0031-9155/56/8/004
Zimmer, L., and Luxen, A. (2012). PET radiotracers for molecular imaging in the brain: past, present and future. *Neuroimage* 61, 363–370. doi: 10.1016/j.neuroimage.2011.12.037

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.